Interesting talk. If it pans out, I think the challenge will be determining when to use leronlimab. There are a lot of inflammatory markers used in medicine, and tmk none of them are specific enough upon which to base targeted therapy. Maybe RANTES is different.
The cost of therapy is also likely to be a problem. Monoclonal antibodies are among the most expensive drugs available, costing thousands-tens of thousands of dollars per dose. Used as cancer immunotherapy, they’ve already pushed the envelope for cost effectiveness. Some of the $ may be offset by saved days of ICU care, but it may be difficult to get insurers to foot the bill for tens of thousands (or more) patients. And that’s just in this county, as it’s doubtful such a drug can be produced at a scale to manage the pandemic elsewhere, especially the developing world.
I hope it continues to show promise. In the meantime, maybe more low tech alternatives like hydrocortisone can keep the immune system in check.